Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER

NCT02206724 is registered in ClinicalTrials.gov with Sharp HealthCare as lead sponsor.

NCT NCT02206724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02206724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER
Lead sponsor
Sharp HealthCare
Phase
Not applicable
Overall status
Withdrawn
Start date
July 16, 2014
Completion date
April 17, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer